Meeting
2022 ASCO Annual Meeting
Characterization and impact of canonical Wnt Signaling Pathway (WSP) alterations on outcomes of metastatic prostate cancer.
Authors
Rana R. McKay
University of California San Diego Health, La Jolla, CA
Rana R. McKay , Julie McGrath , Elizabeth Pan , Alex Farrell , Himisha Beltran , Elisabeth I. Heath , Chadi Nabhan , Charles J. Ryan , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5053)
DOI
10.1200/JCO.2022.40.16_suppl.5053
Abstract #
5053
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC).
First Author: Pedro Isaacsson Velho
Poster
2024 ASCO Genitourinary Cancers Symposium
Canonical Wnt signaling pathway (WSP) alterations in metastatic prostate cancer.
First Author: Sharon Choi
Poster
2023 ASCO Genitourinary Cancers Symposium
Clinical implications of Wnt signaling alterations in patients (pts) with advanced prostate cancer (aPC).
First Author: Amanda Broderick
Poster
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dana E. Rathkopf